Low-Code and No-Code GxP Validation: Fast Configuration Still Needs Defensible Control
Low-code accelerates application delivery but moves critical logic into configuration. Learn how to govern makers, releases, testing, and GxP evidence.
21 CFR Part 11 vs Annex 11: Where They Align and Where Teams Get Trapped
Learn the practical differences between FDA 21 CFR Part 11 and EU GMP Annex 11, why organizations confuse them, and how unified lifecycle governance supports compliance across both frameworks.
CSA vs CSV: What FDA’s Computer Software Assurance Really Changes
FDA’s Computer Software Assurance does not replace Computer System Validation—it modernizes it. Discover how CSA shifts validation from documentation-heavy projects to risk-based, evidence-driven assurance.
GxP Electronic Signatures: Prove the Decision, Not Just the Click
An electronic signature is more than an authenticated click. Learn how to validate identity, authority, meaning, record linkage, and lifecycle integrity.
Why Audit Readiness Is Becoming a Continuous State, Not an Event
Audit readiness is shifting from periodic inspection preparation to continuous operational control. Explore the regulatory drivers, governance principles, and infrastructure needed to maintain an inspection-ready validation state every day.
Digital Validation in 2026: What Changed, What Didn’t
Digital validation in 2026 is shaped by AI, cloud systems, Pharma 4.0, stronger regulatory expectations, and connected validation ecosystems. But intended use, risk, data integrity, traceability, and accountability still remain the foundation.
Data Integrity Is Moving Upstream: Why Life Sciences Teams Need to Prevent Data Problems Before Review
Data integrity can no longer be treated as a final review activity. Modern life sciences teams need upstream controls that prevent data issues at creation, configuration, transfer, testing, approval, and change.
Digital Validation in Life Sciences: Why Modern Compliance Needs More Than Electronic Documents
Digital validation is transforming life sciences, but electronic records alone are no longer enough. Here is why modern compliance needs connected validation systems and why AI-Native Validation Infrastructure is becoming increasingly relevant.
The FDA Didn’t Warn Against AI. It Warned Against Undefended AI
The FDA’s recent warning letter did not say companies should avoid AI. It showed that AI use in regulated environments must be reviewable, risk-based, and defensible. Here is what life sciences teams should really take from it.
From CSV to Continuous Control: Why Validation Is Becoming an Operating Model
Validation is shifting from one-time CSV projects to a continuous operating model. Modern life sciences teams need connected traceability, risk-based assurance, change control, and audit-ready evidence that keeps the validated state current.
